Search results for "Coinfection"

showing 10 items of 126 documents

Prospective evaluation of hepatic steatosis in HIV-infected patients with or without hepatitis C virus co-infection

2012

Background: Limited data are available on hepatic steatosis (HS) in HIV patients who are not infected with hepatitis C virus (HCV). The aims of this study were to assess the prevalence of HS and its risk factors in HIV patients with and without HCV infection, and to evaluate whether HS correlates with advanced liver fibrosis and/or cardiovascular disease risk. Methods: Fifty-seven HIV mono-infected and 61 HIV/HCV co-infected patients were enrolled consecutively. All patients underwent liver ultrasound and transient elastography. The main parameters of liver function, HIV and HCV viral loads, CD4+ cell counts, and data on highly active antiretroviral therapy (HAART) were recorded. Cardiovasc…

Liver CirrhosisMaleSteatosisSettore MED/09 - Medicina InternaLipodystrophyAntiretroviral medicationHIV Infectionsmedicine.disease_causeGastroenterologyHIV/HCV co-infectedLiver diseaseRisk FactorsAntiretroviral Therapy Highly ActivePrevalenceMedicineProspective StudiesSteatosis HIV HIV/HCV co-infected Non-alcoholic fatty liver disease Liver disease Antiretroviral medication Metabolic syndrome LipodystrophyUltrasonographyeducation.field_of_studySettore MED/12 - GastroenterologiaFramingham Risk ScoreCoinfectionvirus diseasesGeneral MedicineMiddle AgedMetabolic syndromeHepatitis CInfectious DiseasesCardiovascular DiseasesFemaleLipodystrophyLiver diseaseViral loadMicrobiology (medical)Adultmedicine.medical_specialtySettore MED/17 - Malattie InfettiveAnti-HIV AgentsHepatitis C virusPopulationInternal medicineHumanseducationbusiness.industryHIVmedicine.diseaseFatty LiverImmunologyMultivariate AnalysisLiver functionbusinessTransient elastographyNon-alcoholic fatty liver disease
researchProduct

Prevalence and risk factors for advanced liver fibrosis in HIV/HCV-coinfected individuals

2010

Liver fibrosis HIV HCV coinfection transient elastography
researchProduct

Evaluating polymicrobial immune responses in patients suffering from tick-borne diseases

2018

Abstract There is insufficient evidence to support screening of various tick-borne diseases (TBD) related microbes alongside Borrelia in patients suffering from TBD. To evaluate the involvement of multiple microbial immune responses in patients experiencing TBD we utilized enzyme-linked immunosorbent assay. Four hundred and thirty-two human serum samples organized into seven categories followed Centers for Disease Control and Prevention two-tier Lyme disease (LD) diagnosis guidelines and Infectious Disease Society of America guidelines for post-treatment Lyme disease syndrome. All patient categories were tested for their immunoglobulin M (IgM) and G (IgG) responses against 20 microbes assoc…

Lyme DiseaseCoinfectionco-infectionsBorrelialcsh:Rlcsh:MedicinezoonoositinfektiotCD57 AntigensImmunoglobulin MROC CurveTick-Borne DiseasesborrelioosiArea Under CurveBorrelia burgdorferiImmunoglobulin GimmuunivasteLymen borrelioosiHumanslcsh:Qlcsh:ScienceinfektiotauditScientific Reports
researchProduct

Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality fr…

2018

Abstract Risk factors (RFs) and mortality data of community‐acquired respiratory virus (CARVs) lower respiratory tract disease (LRTD) with concurrent pulmonary co‐infections in the setting of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is scarce. From January 2011 to December 2017, we retrospectively compared the outcome of allo‐HSCT recipients diagnosed of CARVs LRTD mono‐infection (n = 52, group 1), to those with viral, bacterial, or fungal pulmonary CARVs LRTD co‐infections (n = 15, group 2; n = 20, group 3, and n = 11, group 4, respectively), and with those having bacterial pneumonia mono‐infection (n = 19, group 5). Overall survival (OS) at day 60 after bronchoalveol…

Male0301 basic medicinemedicine.medical_treatmentcommunity acquired respiratory virusHematopoietic stem cell transplantationBronchoalveolar LavageGastroenterology0302 clinical medicineRisk Factorsrespiratory virus co‐infectionsLungRespiratory Tract Infectionsmedicine.diagnostic_testRespiratory tract infectionsCoinfectionHematopoietic Stem Cell TransplantationMiddle AgedCommunity-Acquired InfectionsInfectious Diseasesmedicine.anatomical_structureVirusesvirus-bacterial mixed infectionsRespiratory virusFemaleOriginal Articlerespiratory virus co-infectionsBronchoalveolar Lavage FluidAdultmedicine.medical_specialtyvirus‐bacterial mixed infections030106 microbiologyContext (language use)CMV DNAemiaAntiviral Agents03 medical and health sciencesInternal medicinemedicineHumansTransplantation Homologousallogeneic hematopoietic stem cell transplantationAgedRetrospective StudiesTransplantationLungBacteriabusiness.industryFungiBacterial pneumoniaOriginal Articlesmedicine.diseaseTransplantationBronchoalveolar lavagebusinessimmunodeficiency score index030215 immunology
researchProduct

Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?

2019

AbstractBackgroundAlcohol consumption is a known risk factor for liver disease in HIV-infected populations. Therefore, knowledge of alcohol consumption behaviour and risk of disease progression associated with hazardous drinking are important in the overall management of HIV disease. We aimed at assessing the usefulness of routine data collected on alcohol consumption in predicting risk of severe liver disease (SLD) among people living with HIV (PLWHIV) with or without hepatitis C infection seen for routine clinical care in Italy.MethodsWe included PLWHIV from two observational cohorts in Italy (ICONA and HepaICONA). Alcohol consumption was assessed by physician interview and categorized ac…

Male030508 substance abuseHIV InfectionsSeverity of Illness IndexCohort StudiesLiver disease0302 clinical medicineRisk FactorsEpidemiologyMedicineHIV InfectionAlcohol consumptionAlcohol consumption HIV-infected HIV/HCV co-infection Severe liver disease030212 general & internal medicineeducation.field_of_studyCoinfectionLiver Diseaselcsh:Public aspects of medicineLiver DiseasesHazard ratioHepatitis CMiddle AgedHepatitis CItalyalcohol consumption; HIV-infected; HIV/HCV co-infection; severe liver diseaseCoinfectionFemale0305 other medical scienceHumanCohort studyResearch ArticleAdultmedicine.medical_specialtyAlcohol DrinkingPopulationSevere liver diseaseHIV/HCV co-infectionNO03 medical and health sciencesEnvironmental healthHumansRisk factorAlcohol consumption; HIV-infected; HIV/HCV co-infection; Severe liver disease; Adult; Alcohol Drinking; Cohort Studies; Female; HIV Infections; Hepatitis C; Humans; Italy; Liver Diseases; Male; Middle Aged; Risk Factors; Severity of Illness Index; CoinfectioneducationHIV-infectedbusiness.industryRisk FactorPublic Health Environmental and Occupational Healthlcsh:RA1-1270medicine.diseaseCohort StudiebusinessBMC Public Health
researchProduct

Human fascioliasis infection: gender differences within school-age children from endemic areas of the Nile Delta, Egypt

2007

Summary Several studies have reported a higher prevalence of infection for human fascioliasis among girls than among boys. To investigate this aspect further a sufficiently large data set was assembled comprising of 21 477 subjects with 932 positive cases. Subjects were primary school children covered by a control programme implemented by the Egyptian Ministry of Health and Population in the Nile Delta from 1988 to 2002. Stool analyses were performed by the Kato–Katz thick smear technique for a quantitative diagnosis on the intensity of infection. Both prevalence and intensity of infection, indirectly measured as mean number of eggs per gram of faeces, were significantly higher among girls …

MaleFascioliasismedicine.medical_specialtyHealth BehaviorPopulationHelminthiasisAge DistributionRisk FactorsEpidemiologyPrevalencemedicineHumansSex DistributionRisk factorChildeducationEggs per grameducation.field_of_studybusiness.industryPublic Health Environmental and Occupational HealthGeneral Medicinemedicine.diseaseSchistosomiasis mansoniInfectious DiseasesEl NiñoImmunologyCoinfectionEgyptFemaleParasitologyRural areabusinessDemographyTransactions of the Royal Society of Tropical Medicine and Hygiene
researchProduct

Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action.

1998

Abstract Background/Aims: To investigate the impact of hepatitis B (HBV) and C (HCV) infections on hepatocellular carcinoma (HCC) in Europe. Methods: Five hundred and three patients with HCC, from six liver centers, were included. All 503 sera and 80 liver samples were tested for HBV DNA and HCV RNA by polymerase chain reaction. GBV-C/HGV RNA was also tested in 57 sera. Results: HBsAg and anti-HCV were detected in 19% and 40.1% of the patients, respectively. Serum and liver HBV DNA were detected in 82% and 91% of the HBsAg positive subjects. HBV DNA was also detected in the serum and liver of 33% and 47% of HBsAg negative patients. In this group, serum HBV DNA was more prevalent in anti-HBs…

MaleHBsAgHepatitis B virusCarcinoma HepatocellularGenotypeHepatitis Viral HumanGbv c hgvHepacivirusPolymerase Chain Reactionlaw.inventionSerologylawGenotypeMedicineHumansPolymerase chain reactionAgedHepatitis B Surface AntigensHepatologybusiness.industryFlaviviridaeLiver NeoplasmsGastroenterologyvirus diseasesHepatitis BMiddle Agedmedicine.diseaseHepatitis BVirologyHepatitis Cdigestive system diseasesEuropeLiverHepatocellular carcinomaDNA ViralCoinfectionFemaleViral diseasebusinessJournal of hepatology
researchProduct

Modification of Hepatitis B Virus Infection by Recombinant Leukocyte Alpha A Interferon

1986

A defect in alpha interferon production in patients with chronic type B hepatitis offers a rationale principle for treating this disease with interferon. Two trials with interferon in chronic type B hepatitis indicate that this therapy achieves an elimination of HBsAg and HBeAg significantly higher than spontaneous. Our study and that of others indicate, however, that the response to interferon therapy is dependent on many variables including: the type of interferon, the interferon dose, duration of interferon treatment, sex, sexual preference in men and coinfection with other viruses. As of the multiple modes of action of interferon, a better understanding of viral replication, of the anti…

MaleHBsAgImmunologyAlpha interferonAntibodies Viralmedicine.disease_causeInterferonmedicineHumansImmunology and AllergyHepatitis B e AntigensInterferon alfaHepatitis B virusHepatitis B Surface AntigensDose-Response Relationship Drugbiologybusiness.industryHIVvirus diseasesHomosexualityHematologyHepatitis Bmedicine.diseasebiology.organism_classificationVirologydigestive system diseasesHBeAgHepadnaviridaeInterferon Type IImmunologyCoinfectionDrug EvaluationFemalebusinessmedicine.drugImmunobiology
researchProduct

Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER …

2021

Background: Direct-acting antivirals are highly effective for the treatment of hepatitis C virus (HCV) infection, regardless race/ethnicity. We aimed to evaluate demographic, virological and clinical data of HCV-infected migrants vs. natives consecutively enrolled in the PITER cohort. Methods: Migrants were defined by country of birth and nationality that was different from Italy. Mann-Whitney U test, Chi-squared test and multiple logistic regression were used. Results: Of 10,669 enrolled patients, 301 (2.8%) were migrants: median age 47 vs. 62 years, (p < 0.001), females 56.5% vs. 45.3%, (p < 0.001), HBsAg positivity 3.8% vs. 1.4%, (p < 0.05). Genotype 1b was prevalent in both gro…

MaleHCV genotypesEthnic groupLinked-to-care patientComorbidityHepacivirusLogistic regressionmedicine.disease_causeComorbidities; Direct acting antivirals; HCV Cohort; Linked-to-care patients; Aged; Antiviral Agents; Coinfection; Comorbidity; Female; Hepacivirus; Hepatitis C Chronic; Humans; Italy; Male; Middle Aged; Transients and MigrantsComorbidities0302 clinical medicineMedicineComorbidities; Direct acting antivirals; HCV Cohort; Linked-to-care patientsChronicTransients and MigrantsCoinfectionGastroenterologyvirus diseasesMiddle AgedHepatitis CLife evaluationItaly030220 oncology & carcinogenesisLinked-to-care patientsCohort030211 gastroenterology & hepatologyFemaleComorbiditieHumanHepatitis C virusSettore MED/12 - GASTROENTEROLOGIAAntiviral AgentsDirect acting antivirals03 medical and health sciencesDisease severityHumansAgedAntiviral AgentHepaciviruHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAHepatitis C Chronicmedicine.diseaseComorbiditydigestive system diseasesDirect acting antiviralHCV CohortbusinessDemography
researchProduct

High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Geno…

2015

BACKGROUND Few direct anti-hepatitis C virus (HCV) agents have been studied in difficult-to-treat null responder and cirrhotic human immunodeficiency virus (HIV)-coinfected patients. Daclatasvir and asunaprevir combined with pegylated interferon/ribavirin (peg-IFN/RBV) have shown promising results in HCV-monoinfected patients. METHODS An open-label, single-arm, phase 2 study was conducted in HIV/HCV genotype 1/4-coinfected patients who were null responders to prior peg-IFN/RBV standard therapy and on a raltegravir-based regimen with HIV RNA <400 copies/mL. They received a 4-week lead-in phase with peg-IFN/RBV, followed by 24 weeks of asunaprevir (100 mg twice daily), daclatasvir (60 mg once…

MaleMicrobiology (medical)medicine.medical_specialtyPyrrolidinesDaclatasvir[SDV]Life Sciences [q-bio]PopulationHIV InfectionsHepacivirusAntiviral AgentsGastroenterologychemistry.chemical_compoundPegylated interferonInternal medicinemedicineHumansdaclatasvireducationasunaprevireducation.field_of_study[ SDV ] Life Sciences [q-bio]Coinfectionbusiness.industryRibavirincirrhosisImidazolesvirus diseasesHIVValineHepatitis C ChronicMiddle AgedRaltegravirmedicine.disease3. Good healthRegimenTreatment OutcomeInfectious DiseaseschemistryImmunologyHCVCoinfectionAsunaprevirFemaleCarbamatesbusinessmedicine.drug
researchProduct